SWOG Cancer Research Network
This phase II trial is to answer the question of "can adding the study drug, asciminib to usual treatment improve how chemotherapy works against Ph+ Acute Lymphoblastic Leukemia (ALL) and is this approach better than the usual approach for Ph+ALL?"
PRIMARY OBJECTIVES: I. To assess the rate of major molecular remission (MMR) by polymerase chain reaction (PCR) for BCR-ABL at day 85 in newly diagnosed participants with Philadelphia-chromosome positive Ph+ acute lymphoblastic leukemia (ALL) treated with asciminib, dasatinib and prednisone. SECONDARY OBJECTIVES: I. To estimate the rate of complete remission (with and without complete count recovery, CR/CRi) at day 85 in this participant population. II. To describe disease-free survival (DFS) in this participant population. III. To estimate overall survival (OS) in this participant populat…
Inclusion Criteria: * Participants must have a new diagnosis of Philadelphia chromosome positive (Ph+) ALL by cytogenetics, FISH, or polymerase chain reaction (PCR). Diagnostic specimens must be submitted to the site's local CLIA-approved cytogenetics laboratory and results (cytogenetics, FISH, or PCR) must confirm Ph status prior to registration. * Participants must have BCR-ABL status (p190 or p210) performed but results don't need to be back prior to Step 1 registration. * Participants must have evidence of CD19+ ALL in their marrow or peripheral blood with at least 20% lymphoblasts presen…
Asciminib, Dasatinib, Prednisone, and Methotrexate
Blinatumomab, Dasatinib, Methotrexate, and Dexamethasone
Blinatumomab, Dasatinib, Methotrexate and Dexamethasone
Asciminib, Dasatinib, Prednisone, and Methotrexate